Comparing GeneLink (OTCMKTS:GNLKQ) and Arcellx (NASDAQ:ACLX)

Arcellx (NASDAQ:ACLX) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Arcellx and GeneLink, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	0	0	13	1	3.07
GeneLink	0	0	0	0	N/A

Arcellx presently has a consensus target price of $89.75, indicating a potential upside of 1.77%.

Risk and Volatility

Arcellx has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, GeneLink has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.

Earnings and Valuation

This table compares Arcellx and GeneLink”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$144.75 million	32.60	-$70.69 million	($1.03)	-85.62
GeneLink	N/A	N/A	N/A	N/A	N/A

GeneLink has lower revenue, but higher earnings than Arcellx.

Institutional and Insider Ownership

96.0% of Arcellx shares are owned by institutional investors. 6.2% of Arcellx shares are owned by insiders. Comparatively, 14.2% of GeneLink shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Arcellx and GeneLink’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcellx	-37.23%	-12.42%	-7.30%
GeneLink	N/A	N/A	N/A

Summary

Arcellx beats GeneLink on 5 of the 9 factors compared between the two stocks.

About Arcellx

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.